<code id='29577AD3E6'></code><style id='29577AD3E6'></style>
    • <acronym id='29577AD3E6'></acronym>
      <center id='29577AD3E6'><center id='29577AD3E6'><tfoot id='29577AD3E6'></tfoot></center><abbr id='29577AD3E6'><dir id='29577AD3E6'><tfoot id='29577AD3E6'></tfoot><noframes id='29577AD3E6'>

    • <optgroup id='29577AD3E6'><strike id='29577AD3E6'><sup id='29577AD3E6'></sup></strike><code id='29577AD3E6'></code></optgroup>
        1. <b id='29577AD3E6'><label id='29577AD3E6'><select id='29577AD3E6'><dt id='29577AD3E6'><span id='29577AD3E6'></span></dt></select></label></b><u id='29577AD3E6'></u>
          <i id='29577AD3E6'><strike id='29577AD3E6'><tt id='29577AD3E6'><pre id='29577AD3E6'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:29975
          James Comer -- coverage from STAT
          Rep. James Comer, chair of the House Oversight Committee Kevin Dietsch/Getty Images

          WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of medicines — but don’t think they’ve forgotten drugmakers have a role in high drug prices.

          Two lawmakers, including a Republican, questioned PhRMA Chief Operating Officer Lori Reilly about just how much her group was spending on its major campaigns against PBMs this year. Both Reps. Summer Lee (D-Pa.) and Eric Burlison (R-Mo.) used their time to question drugmakers over their spending on lawsuits against Medicare drug price negotiation and ad campaigns against pharmacy benefit managers.

          advertisement

          Although Lee started off bashing PBMs for the fees they charge drugmakers, she quickly aimed her fire back on pharma. She said brand drugmakers charge Americans double what they charge other countries, and she asked why several drugmakers are suing the federal government over Medicare’s drug price negotiation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

          ChristineKao/STATTheFoodandDrugAdministration’sapprovalonFridayoftwogenetherapiesforsicklecelldiseas

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Fetal surgery at risk from Dobbs and new abortion restrictions

          AdobeTheconceptoffetalsurgerycapturestheimaginationwhen,fromtimetotime,itmakestheheadlines.Fewpregna